       Document 1085
 DOCN  M94A1085
 TI    Enrollment of HIV-infected minority women into clinical trials.
 DT    9412
 AU    Sheffield D; Kloser P; Gill C; Correll P; UMDNJ: NJ Med School, Newark.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):212 (abstract no. PB0861). Unique
       Identifier : AIDSLINE ICA10/94371490
 AB    OBJECTIVE: To determine the factors important for the enrollment,
       maintenance and compliance of minority women in clinical trials. METHOD:
       A nurse-clinician providing clinical care to inner-city minority women
       asked open-ended questions about enrollment, maintenance and compliance
       in a clinical trial. All questions were answered by 33 women currently
       enrolled in a clinical trial. RESULTS: Patient characteristics included
       an average age of 41.1 years, 85% African-American, 9% Latina, 6%
       Caucasian. The four most common reasons to enter a clinical trial were
       to live longer, physician trust, help myself and help others. The most
       common barriers to staying the trial were fear of the drugs and
       difficulty in taking too many pills. The most common reasons to stay in
       trial were to get better clinical care, to feel better and to live
       longer. Although 23% of the women wished that they could stop taking
       their pills, 94% said that they would enroll again if they had it to do
       over. CONCLUSIONS: It is ethically important to include women and
       minorities in clinical trials. Physician trust, improved clinical care
       and a desire to prolong life were important considerations in the
       enrollment and maintenance of the women in the trials. The results
       suggest that inner-city women with a trusted primary care provider can
       be willing and compliant clinical trial participants.
 DE    Adult  Attitude  *Clinical Trials  Female  Human  HIV
       Infections/*THERAPY  *Minority Groups  Motivation  Patient Compliance
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

